Logo
Unionpedia
Communication
Get it on Google Play
New! Download Unionpedia on your Android™ device!
Install
Faster access than browser!
 

Rimonabant

Index Rimonabant

Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug that was first approved in Europe in 2006 but was withdrawn worldwide in 2008 due to serious psychiatric side effects; it was never approved in the United States. [1]

22 relations: Anorectic, Anti-obesity medication, Body mass index, Cannabinoid receptor type 1, Committee for Medicinal Products for Human Use, CYP3A4, Diabetes mellitus, Drug development, Drug discovery, Dyslipidemia, European Commission, European Medicines Agency, Food and Drug Administration, Gastroenteritis, Inverse agonist, Kidney, Liver, Postmarketing surveillance, Receptor (biochemistry), Risk–benefit ratio, Sanofi, Therapeutic index.

Anorectic

An anorectic or anorexic is a drug which reduces appetite, resulting in lower food consumption, leading to weight loss.

New!!: Rimonabant and Anorectic · See more »

Anti-obesity medication

Anti-obesity medication or weight loss drugs are pharmacological agents that reduce or control weight.

New!!: Rimonabant and Anti-obesity medication · See more »

Body mass index

The body mass index (BMI) or Quetelet index is a value derived from the mass (weight) and height of an individual.

New!!: Rimonabant and Body mass index · See more »

Cannabinoid receptor type 1

The cannabinoid type 1 receptor, often abbreviated as CB1, is a G protein-coupled cannabinoid receptor located in the central and peripheral nervous system.

New!!: Rimonabant and Cannabinoid receptor type 1 · See more »

Committee for Medicinal Products for Human Use

The Committee for Medicinal Products for Human Use (CHMP), formerly known as Committee for Proprietary Medicinal Products (CPMP), is the European Medicines Agency's committee responsible for elaborating the agency's opinions on all issues regarding medicinal products for human use.

New!!: Rimonabant and Committee for Medicinal Products for Human Use · See more »

CYP3A4

Cytochrome P450 3A4 (abbreviated CYP3A4) is an important enzyme in the body, mainly found in the liver and in the intestine.

New!!: Rimonabant and CYP3A4 · See more »

Diabetes mellitus

Diabetes mellitus (DM), commonly referred to as diabetes, is a group of metabolic disorders in which there are high blood sugar levels over a prolonged period.

New!!: Rimonabant and Diabetes mellitus · See more »

Drug development

Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery.

New!!: Rimonabant and Drug development · See more »

Drug discovery

In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.

New!!: Rimonabant and Drug discovery · See more »

Dyslipidemia

Dyslipidemia is an abnormal amount of lipids (e.g. triglycerides, cholesterol and/or fat phospholipids) in the blood.

New!!: Rimonabant and Dyslipidemia · See more »

European Commission

The European Commission (EC) is an institution of the European Union, responsible for proposing legislation, implementing decisions, upholding the EU treaties and managing the day-to-day business of the EU.

New!!: Rimonabant and European Commission · See more »

European Medicines Agency

The European Medicines Agency (EMA) is a European Union agency for the evaluation of medicinal products.

New!!: Rimonabant and European Medicines Agency · See more »

Food and Drug Administration

The Food and Drug Administration (FDA or USFDA) is a federal agency of the United States Department of Health and Human Services, one of the United States federal executive departments.

New!!: Rimonabant and Food and Drug Administration · See more »

Gastroenteritis

Gastroenteritis, also known as infectious diarrhea, is inflammation of the gastrointestinal tract -- the stomach and small intestine.

New!!: Rimonabant and Gastroenteritis · See more »

Inverse agonist

In the field of pharmacology, an inverse agonist is an agent that binds to the same receptor as an agonist but induces a pharmacological response opposite to that agonist.

New!!: Rimonabant and Inverse agonist · See more »

Kidney

The kidneys are two bean-shaped organs present in left and right sides of the body in vertebrates.

New!!: Rimonabant and Kidney · See more »

Liver

The liver, an organ only found in vertebrates, detoxifies various metabolites, synthesizes proteins, and produces biochemicals necessary for digestion.

New!!: Rimonabant and Liver · See more »

Postmarketing surveillance

Postmarketing surveillance (PMS) (also post market surveillance) is the practice of monitoring the safety of a pharmaceutical drug or medical device after it has been released on the market and is an important part of the science of pharmacovigilance.

New!!: Rimonabant and Postmarketing surveillance · See more »

Receptor (biochemistry)

In biochemistry and pharmacology, a receptor is a protein molecule that receives chemical signals from outside a cell.

New!!: Rimonabant and Receptor (biochemistry) · See more »

Risk–benefit ratio

A risk–benefit ratio is the ratio of the risk of an action to its potential benefits.

New!!: Rimonabant and Risk–benefit ratio · See more »

Sanofi

Sanofi S.A. is a French multinational pharmaceutical company headquartered in Gentilly, France, as of 2013 the world's fifth-largest by prescription sales.

New!!: Rimonabant and Sanofi · See more »

Therapeutic index

The therapeutic index (TI; also referred to as therapeutic ratio) is a comparison of the amount of a therapeutic agent that causes the therapeutic effect to the amount that causes toxicity.

New!!: Rimonabant and Therapeutic index · See more »

Redirects here:

ATC code A08AX01, ATCvet code QA08AX01, Accomplia, Acomphia, Acomplia, C22H21Cl3N4O, Rimonobant, Rimoslim, Riobant, SR-141,716, SR-141716A, SR141716, SR141716A, Slimona, Zimulti.

References

[1] https://en.wikipedia.org/wiki/Rimonabant

OutgoingIncoming
Hey! We are on Facebook now! »